Women with Rheumatic Disease (11.4.2022)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?
The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.
Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
An online survey of random COVID-19 infected persons shows that arthralgia and myalgia are common consequences to COVID-19 infection.
The Lasker Foundation has announced the winners of its 2022 Lasker Awards: Richard O. Hynes (Massachusetts Institute of Technology), Erkki Ruoslahti (Sanford Burnham Prebys) and Timothy A.
Thanks to all of you for your kind comments and great reviews of our weekly podcast.
A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).
Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from RheumNow.com.
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links: